EM-amoxicillin 3 x 10 days
Phase 3Small molecule
EM-amoxicillin 3 x 10 days is one of 29 small molecule programs targeting Erythema. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
50 competitors in Erythema
#DrugCompanyPhaseTrials
1Lamprene
NovartisApproved
Trexall
Alnylam PharmaceuticalsApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Amoxil
GGlobal Antibiotics Research and Development Partnership
Approved
Accutane
CConrado Roberto Hoffmann Filho
Approved
Botulinum Toxin a
GSKApproved
Trimethoprim-Sulfamethoxazole
AstellasApproved
Alphagan
NovartisPhase 3
Ceftin
GGlaxo Dba Glaxosmithkline
Approved
Rhofade
KKenvue Brands
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for EM-amoxicillin 3 x 10 days. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details